<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795782</url>
  </required_header>
  <id_info>
    <org_study_id>2008-09-048</org_study_id>
    <nct_id>NCT00795782</nct_id>
  </id_info>
  <brief_title>Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma</brief_title>
  <official_title>Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the prophylactic ipsilateral central lymph
      node dissection is equally effective in the management of papillary thyroid
      microcarcinoma(PTMC) to the bilateral central lymph node dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The extent, the advantage and disadvantage of prophylactic central lymph node dissection was
      not fully established up to now in papillary thyroid microcarcinoma.

      Prophylactic bilateral central lymph node dissection can give a important clinical
      information about the status of lymph nodes, and possibly guide a further adjuvant treatment.
      However, it causes high postoperative morbidity, including hypocalcemia and hoarseness. In
      this respect, some advocate no central lymph node dissection in prophylactic settings.

      Thus, we aimed to prove the efficacy of prophylactic ipsilateral central lymph node
      dissection in thyroid papillary microcarcinoma, compared to the bilateral dissection and no
      dissection.

      Type of Study design: Prospective randomized, controlled double-blinded (to subjects and
      observers) study.

      Group I: Limited/ipsilateral central lymph node dissection (UniCND) Group II:
      Comprehensive/bilateral central lymph node dissection (BiCND) Group III: No central lymph
      node dissection (NoCND)

      Outcomes: vocal cord palsy, hypocalcemia, locoregional recurrence, distant metastasis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence (Thyroglobulin level, antiTG level, results of follow-up imaging tools)</measure>
    <time_frame>3 year after initial treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications(hypocalcemia, hoarseness)</measure>
    <time_frame>up to 3 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>UniCND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Limited/ipsilateral central lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiCND</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comprehensive/bilateral central lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoCND</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No central lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylactic central lymph node dissection</intervention_name>
    <description>prophylactic ipsilateral versus bilateral central lymph node dissection</description>
    <arm_group_label>UniCND</arm_group_label>
    <arm_group_label>BiCND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 70

          -  Sonographically node-negative cytology confirmed thyroid papillary carcinoma

          -  Tumor size less than 1 cm in sonography

          -  Tumor confined to the one lobe of the thyroid gland

          -  One who provides the informed consent

        Exclusion Criteria:

          -  History of radiation treatment to head and neck area

          -  History of other malignancy except thyroid cancer

          -  Poor performance status (ECOG 3-4)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-Sin Jeong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Otorhinolaryngology-Head and Neck Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Son YI, Jeong HS, Baek CH, Chung MK, Ryu J, Chung JH, So YK, Jang JY, Choi J. Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma: comparison of limited versus comprehensive lymph node dissection in a 2-year safety study. Ann Surg Oncol. 2008 Jul;15(7):2020-6. doi: 10.1245/s10434-008-9928-8. Epub 2008 May 6.</citation>
    <PMID>18459004</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Papillary thyroid carcinoma</keyword>
  <keyword>Lymph node dissection</keyword>
  <keyword>Lymph node metastasis</keyword>
  <keyword>Prophylactic node dissection</keyword>
  <keyword>Central lymph node metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

